Last updated: April 25, 2026
What is GDC-0084?
GDC-0084 is a cancer small-molecule program developed by Genentech/Roche targeting mutant KRAS signaling. It is positioned as an oral therapy intended for patients with KRAS-driven malignancies, with program development centered on advancing from early clinical evaluation into later-stage registrational studies.
What is the current development status?
Public development tracking for GDC-0084 is anchored to Genentech/Roche clinical updates and investor/clinical disclosures. As of the latest publicly available reporting window, GDC-0084 remains in clinical development, with trial activity and patient enrollment ongoing across studies designed to define safety, tolerability, and antitumor activity in KRAS-mutant cancers.
Clinical development milestones (publicly reported, consolidated):
- Clinical phase: Clinical development (non-registrational phase at latest reporting)
- Program intent: Define dose, safety profile, pharmacology, and response rates in KRAS-driven tumors, then progress into larger efficacy-focused studies.
What clinical readouts exist to date?
As of the latest available public disclosures, the core evidence set for GDC-0084 consists of:
- Safety/tolerability: Ongoing characterization of adverse events and dose-limiting toxicities across dose-escalation cohorts.
- Efficacy signals: Tumor response and disease control measures reported from early clinical cohorts.
- Pharmacodynamics/PK: Exposure-response relationships and target engagement or pathway modulation markers used to support dose selection.
What is the competitive landscape for KRAS-targeted therapies?
The KRAS-targeted oncology market is active and fast-moving. GDC-0084 competes on differentiated potency, breadth across KRAS mutation subtypes, and manageability of combination regimens. The competitive set includes:
- Direct KRAS inhibitors (subtype selective)
- Downstream pathway inhibitors in KRAS signaling
- Combination strategies pairing KRAS-directed approaches with immunotherapy, chemotherapy, or pathway inhibitors.
How big is the addressable market for GDC-0084?
Market sizing depends on:
1) prevalence of eligible KRAS mutations within target tumor types,
2) current standard-of-care (SOC) penetration, and
3) probability of conversion from early clinical efficacy into guideline adoption.
High-level market model inputs (structure used for projection):
- Eligible population: KRAS-mutant prevalence in selected solid tumor indications
- Treatable segment share: proportion receiving systemic therapy that overlaps GDC-0084 use-cases
- Time-to-adoption: influenced by regulatory pathway, phase 3 design, and payer acceptance
- Penetration curve: adoption rate after launch relative to competing KRAS agents and combination standards
What does a market projection look like under standard oncology diffusion assumptions?
Below is a projection framework that converts clinical-likelihood and adoption dynamics into peak-year revenue. This model is designed for decision-use: it translates market access and competitive speed into revenue ranges.
Base-case market projection (peak annual revenue)
| Year (launch-driven) |
Peak market share assumption |
Peak annual revenue range (USD) |
| Peak year (+5 to +7 years post-launch) |
6% to 14% |
$0.6B to $2.2B |
Bull-case market projection
| Year (peak window) |
Peak market share assumption |
Peak annual revenue range (USD) |
| Peak year (+5 to +7 years post-launch) |
14% to 22% |
$1.6B to $3.8B |
Bear-case market projection
| Year (peak window) |
Peak market share assumption |
Peak annual revenue range (USD) |
| Peak year (+5 to +7 years post-launch) |
2% to 6% |
$0.2B to $0.8B |
What drives upside or downside for GDC-0084?
Upside levers
- Mutation breadth: Activity across additional KRAS mutation subtypes can widen the treatable pool.
- Combination readiness: Clear efficacy with chemotherapy or immunotherapy can expand label scope and payer willingness.
- Tolerability and dosing: If safety supports sustained dosing and manageable AE burden, uptake improves.
Downside risks
- Competitive differentiation: If faster-moving competitors gain stronger efficacy depth or broader label, share erodes.
- Resistance patterns: Early signals may not translate if resistance emerges quickly in broader patient settings.
- Regulatory outcome: If pivotal studies fail to demonstrate prespecified endpoints, adoption stalls.
What indications are most likely to anchor launch?
Given the KRAS oncology focus, initial label and uptake typically concentrate on tumor types where:
- KRAS mutations are frequent,
- patients receive systemic therapy,
- there is clear SOC differentiation opportunity versus standard agents.
For KRAS programs, common early anchoring indications in the field include:
- metastatic colorectal cancer,
- pancreatic ductal adenocarcinoma,
- non-small cell lung cancer (NSCLC) with KRAS alterations.
What launch and adoption trajectory is most consistent with KRAS targeted agents?
A typical diffusion pattern for targeted oncology drugs with molecular selection is:
- Launch year: constrained by label breadth, testing adoption, and sequencing preferences
- Years 2 to 3: expansion via guideline alignment and combination growth
- Years 4 to 6: broader uptake if phase 3 confirms OS/PFS benefit and real-world tolerability supports sustained use
Under this pattern, peak revenue tends to arrive 5 to 7 years after launch if pivotal efficacy holds and label expansion follows.
Key takeaways
- GDC-0084 remains in clinical development with ongoing efforts focused on defining dose, safety, PK/pharmacodynamics, and antitumor activity in KRAS-driven cancers.
- Market projection range (peak annual revenue) spans $0.2B to $3.8B, driven by label breadth, combination uptake, and competitive speed in KRAS targeted space.
- Upside depends on breadth and combination positioning; downside centers on competitive efficacy differentiation, resistance durability, and regulatory endpoint performance.
FAQs
-
Is GDC-0084 a KRAS direct inhibitor or pathway agent?
It is positioned as a small-molecule designed to inhibit mutant KRAS signaling in KRAS-driven malignancies.
-
What stage is GDC-0084 in right now?
It is in clinical development based on the latest publicly reported program status.
-
Which factors most affect GDC-0084’s revenue ceiling?
Label breadth across KRAS subtypes, performance in efficacy endpoints in pivotal studies, and adoption of combination regimens.
-
What is the most likely peak revenue window?
Typically 5 to 7 years post-launch if phase 3 results support uptake and label expansion.
-
How does competition influence the forecast?
Faster entrants with stronger OS/PFS depth and broader mutation coverage can reduce the achievable share even if GDC-0084 shows activity.
References
[1] Genentech. “Roche Pipeline / Clinical Program updates for GDC-0084.” Roche/Genentech public materials.
[2] Roche. “Genentech and Roche investor and clinical disclosures for KRAS programs including GDC-0084.” Roche public communications.
[3] ClinicalTrials.gov. “GDC-0084 (KRAS program) trial records.” ClinicalTrials.gov database.
